The Benova Mouth Rinse System has demonstrated a 17% reduction in the inflammatory marker TNF-Alpha within just two minutes of application, according to a study presented at the 2025 Diabetic Limb Salvage Conference. This finding is significant for the millions worldwide suffering from conditions like oral mucositis and canker sores, where TNF-Alpha plays a critical role in inflammation and tissue damage.
Conducted by Dr. Daniel J. Gibson at the University of Alabama Capstone College of Nursing, the research utilized an in vitro model to simulate inflamed oral mucosa, common in patients undergoing cancer therapy or with chronic inflammatory wounds. The study's results suggest that Benova offers a fast-acting anti-inflammatory solution without the need for lidocaine, steroids, or prescription medications.
Bill Kling, co-founder of Benova, emphasized the correlation between the study's findings and anecdotal evidence from users who report rapid pain relief and healing of oral ulcers. The presentation of these results at the Diabetic Limb Salvage Conference underscores the potential of Benova in wound care and tissue regeneration, particularly for diabetic foot and limb wounds.
The Benova Mouth Rinse System, designed for conditions like stomatitis and oral mucositis, is already in use by healthcare professionals to provide immediate relief to patients. This study not only validates the product's mechanism of action but also highlights its importance in improving quality of life for those with inflammatory oral conditions.
